Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy.
A case of persistent cerebellar dysfunction following high-dose cytosine arabinoside (Ara-C) treatment of acute myelogenous leukemia is reported. The symptoms developed after a cumulative dose of 24 g/m2, and 6 months after the start of symptoms, the signs of cerebellar damage were unchanged. The symptoms aggravated during a subsequent low-dose therapy with Ara-C, 15 mg twice daily. This supports the presumption that this adverse effect is caused by the cumulative dose rather than by high plasma concentrations.
Boesen
P
P
Department of Haematology and Internal Medicine, Aalborg Hospital, Denmark.
Fallingborg
J
J
Spaun
E
E
D000328:Adult; D002526:Cerebellar Diseases / Q000139:chemically induced* / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D011689:Purkinje Cells / Q000473:pathology
D003561:Cytarabine